Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
BMC Cancer
; 14: 277, 2014 Apr 22.
Article
en En
| MEDLINE
| ID: mdl-24755296
ABSTRACT
BACKGROUND:
Colorectal cancer (CRC) is a disease of the elderly. However, geriatric patients are often excluded from clinical trials. The combination of capecitabine, oxaliplatin and bevacizumab (XELOX/BEV) has not been assessed in an elderly population.METHODS:
We conducted a phase II study of XELOX plus bevacizumab combination as first line treatment in elderly patients with metastatic CRC. Treatment consisted of capecitabine 750 mg/m2 twice a day during days 1-7, oxaliplatin 85 mg/m2 and bevacizumab 5 mg/kg on day 1. Treatment was repeated every 14 days. The primary endpoint was overall response rate.RESULTS:
In the 48 enrolled patients response rate according was 46.8% (95% CI 32.54%-61.07%), while 13 patients had stable disease, for an overall disease control rate of 74.4% (95% CI 57.8-91.2). Progression free survival was 7.9 months (95% CI 5.9-9.8 months) and the median overall survival 20.1 months (95% CI 15.6-25.7 months). Response rate and progression free survival has been correlated with baseline albumin and haemoglobin levels. There was one treatment-related death. Grade 3-4 toxicities were asthenia (4.2%), neurotoxicity (2.1%) and diarrhea 6.3%).CONCLUSIONS:
The combination of capecitabine, oxaliplatin and bevacizumab is an effective and safe combination for the treatment of elderly patients with metastatic CRC. TRIAL REGISTRATION Clinical trials NCT01024504, 26 November 2010.
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Anciano
/
Neoplasias Colorrectales
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Factores de Edad
Tipo de estudio:
Clinical_trials
Límite:
Aged80
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
BMC Cancer
Asunto de la revista:
NEOPLASIAS
Año:
2014
Tipo del documento:
Article